Lxbio inaugurates pioneering advanced therapies laboratory in Lisbon

Lxbio has inau­gu­rat­ed the first lab­o­ra­to­ry in the Iber­ian Penin­su­la ded­i­cat­ed to the devel­op­ment of CAR‑T cells and mon­o­clon­al anti­bod­ies, mark­ing a major mile­stone for biotech­nol­o­gy in Por­tu­gal. Locat­ed at the Fac­ul­ty of Phar­ma­cy of the Uni­ver­si­ty of Lis­bon, the new facil­i­ty rep­re­sents an ini­tial invest­ment of €4 mil­lion, with total invest­ment expect­ed to reach €20 mil­lion over the next three years.

The inau­gu­ra­tion cer­e­mo­ny was attend­ed by Portugal’s Min­is­ter of Health, Ana Paula Mar­tins, who high­light­ed the strate­gic impor­tance of sci­ence, inno­va­tion and biotech­nol­o­gy in strength­en­ing the nation­al health­care sys­tem. She empha­sized that this lab­o­ra­to­ry sig­nif­i­cant­ly enhances Portugal’s sci­en­tif­ic and tech­no­log­i­cal capac­i­ty, fos­ter­ing clos­er col­lab­o­ra­tion between acad­e­mia, indus­try and the State, while help­ing to attract tal­ent and inter­na­tion­al invest­ment.

The lab­o­ra­to­ry will oper­ate as a Con­tract Research Orga­ni­za­tion (CRO), sup­port­ing phar­ma­ceu­ti­cal com­pa­nies, start-ups and aca­d­e­m­ic insti­tu­tions in the tran­si­tion from pre-clin­i­cal research to ear­ly clin­i­cal devel­op­ment. Its first inter­na­tion­al con­tract has already been signed with the Swiss com­pa­ny T‑Oncology, under­lin­ing the project’s glob­al appeal.

Spe­cial­iz­ing in cut­ting-edge ther­a­pies for onco­log­i­cal and immune dis­eases, the facil­i­ty posi­tions Lis­bon as an emerg­ing hub of excel­lence in biotech­nol­o­gy and places Por­tu­gal firm­ly on the Euro­pean map for advanced ther­a­peu­tic devel­op­ment.

Leave a Reply

Your email address will not be published. Required fields are marked *